secwatch.observer — SEC 8-K summary
======================================

Issuer:     MoonLake Immunotherapeutics (MLTX)
CIK:        0001821586
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001821586-23-000020
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MoonLake Q3 cash $496M; positive Phase 2 data for sonelokimab in HS and PsA
---------------------------------------------------------------------------

- Cash & equivalents $496.0M at Sept 30, 2023, expected to fund Phase 3 programs and regulatory filings.
- Positive full 24-week data from Phase 2 MIRA trial in hidradenitis suppurativa announced.
- Landmark 12-week data from Phase 2 ARGO trial in psoriatic arthritis presented.
- R&D expenses $7.6M in Q3 (down from $8.7M Q2); G&A expenses $5.4M (up from $4.5M).
- Phase 3 initiation targeted for 2024; End of Phase 2 FDA meeting in December 2023; 24-week ARGO data expected Q1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821586/000182158623000020/0001821586-23-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821586/000182158623000020/mnlk-20231114.htm
  HTML page:      https://secwatch.observer/filing/0001821586-23-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer